Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Immunoprecipitation01:20

Immunoprecipitation

6.7K
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
6.7K
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

277
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
277

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Daratumumab as rescue therapy in refractory recurrent FSGS after kidney transplantation: a case series.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Kidney international·2026
Same author

Anti-nephrin antibodies in pediatric nephrotic syndrome: a new paradigm.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Functional characterization of podocyte-expressed THSD7A in experimental membranous nephropathy.

JCI insight·2026
Same author

Effect of Steroids on Anti-nephrin Autoantibodies and B cells in Minimal Change Disease.

Kidney international reports·2026
Same author

Structural modeling and functional characterization of a novel gain-of-function TLR8 variant causing severe inflammatory syndrome.

JCI insight·2026

Related Experiment Video

Updated: Jan 7, 2026

Murine Bilateral Renal Lymphadenectomy
06:20

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

8

Toward precision immunotherapy in nephrology: 1 step forward.

Nicola M Tomas1

  • 1III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Hamburg Center for Translational Immunology (HCTI), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Kidney International
|January 4, 2026
PubMed
Summary

Chimeric autoantibody receptor T cells show promise for treating membranous nephropathy by targeting the source of harmful autoantibodies. This approach offers high specificity for eliminating autoreactive B cells involved in phospholipase A2 receptor 1-associated disease.

More Related Videos

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.6K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.1K

Related Experiment Videos

Last Updated: Jan 7, 2026

Murine Bilateral Renal Lymphadenectomy
06:20

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

8
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.6K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.1K

Area of Science:

  • Immunology
  • Nephrology
  • Cell Therapy

Background:

  • Membranous nephropathy is an autoimmune kidney disease.
  • Autoantibodies against phospholipase A2 receptor 1 (PLA2R1) are the primary cause.
  • Targeting the source of these autoantibodies, autoreactive B cells, is a potential therapeutic strategy.

Purpose of the Study:

  • To evaluate the feasibility of using chimeric autoantibody receptor (CAAR) T cells to target and eliminate autoreactive B cells in PLA2R1-associated membranous nephropathy.
  • To provide evidence for the specificity and potential of CAAR T cell therapy.

Main Methods:

  • Development and application of chimeric autoantibody receptor T cells.
  • Selective elimination of autoreactive B cells in a model of membranous nephropathy.

Main Results:

  • Demonstrated the feasibility of CAAR T cells for targeting B cells in PLA2R1-associated membranous nephropathy.
  • Showcased the potential for highly specific elimination of disease-causing cells.

Conclusions:

  • CAAR T cell therapy presents a promising, highly specific approach for treating membranous nephropathy.
  • Further research is needed to address translational questions and evaluate clinical potential.